Monograph is a life sciences venture firm founded by a team of seasoned biotech investors and company builders. Led by our chair Fred Cohen (Managing Partner at TPG Biotech and Vida Ventures), we have 12 prior funds between the partners, with 37 lead investments and 22 exits over the last two decades. Monograph Fund I (MgC I) is currently invested in 10 therapeutics and pharma services businesses and has fully exited one position. MgC I has one publicly traded position with others approaching IPO-readiness. We are trans-Atlantic, with offices in San Francisco and London.